Target Validation Information
TTD ID T67684
Target Name Muscarinic acetylcholine receptor M3 (CHRM3)
Type of Target
Successful
Drug Potency against Target Atropine Drug Info Ki = 0.5 nM [18]
Darifenacin Drug Info Ki = 1.58 nM [18]
Pirenzepine Drug Info Ki = 125 nM [18]
Succinylcholine Drug Info Ki = 18450 nM [19]
Tolterodine Drug Info Ki = 6.3 nM [18]
1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Drug Info IC50 = 15 nM [12]
1,1-diphenyl-2-(3-tropanyl)ethanol Drug Info IC50 < 10 nM [8]
1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Drug Info Ki = 10700 nM [2]
2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Drug Info Ki = 6.7 nM [17]
2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Drug Info IC50 = 1928 nM
3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Drug Info IC50 = 5696 nM
3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Drug Info IC50 = 16000 nM [3]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [10]
6-Dimethylamino-2-methyl-hex-4-ynal oxime Drug Info IC50 = 13230 nM
7-Dimethylamino-3-methyl-hept-5-yn-2-one Drug Info IC50 = 101 nM
7-Dimethylamino-hept-5-yn-2-one Drug Info IC50 = 68 nM
7-Pyrrolidin-1-yl-hept-5-yn-2-one Drug Info IC50 = 7280 nM
ACECLIDINE Drug Info IC50 = 510 nM [15]
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Drug Info Ki = 680 nM [16]
Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Drug Info Ki = 440 nM [1]
BRL-55473 Drug Info IC50 = 470 nM
Cremastrine Drug Info IC50 = 126 nM [4]
FLUMEZAPINE Drug Info IC50 = 80 nM [11]
FM1-10 Drug Info Ki = 24 nM [7]
FM1-43 Drug Info Ki = 30 nM [7]
GNF-PF-5618 Drug Info Ki = 130 nM [5]
ISOCLOZAPINE Drug Info IC50 = 55 nM [9]
ISOLOXAPINE Drug Info IC50 = 49 nM [14]
N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Drug Info IC50 = 21.6 nM
N-DESMETHYLCLOZAPINE Drug Info Ki = 90 nM [10]
N-methoxyquinuclidine-3-carboximidoyl chloride Drug Info IC50 = 1100 nM
N-methoxyquinuclidine-3-carboximidoyl fluoride Drug Info IC50 = 2000 nM
NOCARDIMICIN A Drug Info Ki = 1250 nM [5]
Nocardimicin C Drug Info Ki = 1000 nM [5]
Nocardimicin D Drug Info Ki = 230 nM [5]
Nocardimicin F Drug Info Ki = 1330 nM [5]
Noccardimicin E Drug Info Ki = 970 nM [5]
Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Drug Info Ki = 11400 nM [1]
SULFOARECOLINE Drug Info IC50 = 1.4 nM [13]
UCB-101333-3 Drug Info Ki = 3.2 nM [6]
Action against Disease Model Tiotropium Drug Info Tiotropi uM concentration-dependently inhibited pulmonary neutrophilic inflammation with IC50: 0.058 mg/mL
References
REF 1 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
REF 2 Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
REF 3 Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
REF 4 Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
REF 5 Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
REF 6 Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80.
REF 7 Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
REF 8 Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2.
REF 9 Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
REF 10 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
REF 11 Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
REF 12 Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
REF 13 Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
REF 14 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
REF 15 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
REF 16 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
REF 17 Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
REF 18 Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14.
REF 19 Receptor binding thermodynamics at the neuronal nicotinic receptor. Curr Top Med Chem. 2004;4(3):361-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.